Search

Your search keyword '"Giles F. J."' showing total 405 results
Start Over Author "Giles F. J."
405 results on '"Giles F. J."'

1. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

Author

Rosti, G, Brummendorf, T, Gjertsen, B, Giraldo-Castellano, P, Castagnetti, F, Gambacorti-Passerini, C, Ernst, T, Zhao, H, Kuttschreuter, L, Purcell, S, Giles, F, Hochhaus, A, Rosti G., Brummendorf T. H., Gjertsen B. T., Giraldo-Castellano P., Castagnetti F., Gambacorti-Passerini C., Ernst T., Zhao H., Kuttschreuter L., Purcell S., Giles F. J., Hochhaus A., Rosti, G, Brummendorf, T, Gjertsen, B, Giraldo-Castellano, P, Castagnetti, F, Gambacorti-Passerini, C, Ernst, T, Zhao, H, Kuttschreuter, L, Purcell, S, Giles, F, Hochhaus, A, Rosti G., Brummendorf T. H., Gjertsen B. T., Giraldo-Castellano P., Castagnetti F., Gambacorti-Passerini C., Ernst T., Zhao H., Kuttschreuter L., Purcell S., Giles F. J., and Hochhaus A.

Abstract

In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome–positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported. Cumulative major molecular response rates at any time on treatment were 73.6%, 64.5%, and 74.1% in patients <65, 65–74, and ≥75 years of age, and 77.9%, 63.0%, and 59.3% in patients with mCCI scores 2, 3, and ≥4, respectively. Patients <65, 65–74, and ≥75 years of age experienced grade 3/4 treatment-emergent adverse events (TEAEs) at rates of 74.7%, 78.8%, and 96.4% and permanent discontinuations due to AEs at rates of 22.1%, 39.4%, and 46.4%, respectively. In patients with mCCI 2, 3, and ≥4, respective rates of grade 3/4 TEAEs were 77.8%, 77.8%, and 86.7%, and permanent discontinuations due to AEs were 25.3%, 33.3%, and 43.3%. In conclusion, a substantial proportion of patients maintained/achieved cytogenetic and molecular responses across age groups and mCCI scores. Older patients (≥75 years) and those with high comorbidity burden (mCCI ≥4) may require more careful monitoring due to the increased risk of TEAEs. Clinicaltrials.gov: NCT02228382.

Published
2024

7. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Author

Hochhaus, A, Rosti, G, Cross, N CP, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, and Giles, F J

Published
2016
Full Text
View/download PDF

25. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Author

Hochhaus, A, Gambacorti Passerini, C, Abboud, C, Gjertsen, B, Brummendorf, T, Smith, B, Ernst, T, Giraldo-Castellano, P, Olsson-Stromberg, U, Saussele, S, Bardy-Bouxin, N, Viqueira, A, Leip, E, Russell-Smith, T, Leone, J, Rosti, G, Watts, J, Giles, F, Abruzzese, E, Akard, L, Bosi, A, Cervantes, F, Charbonnier, A, Di Raimondo, F, Etienne, G, Garcia Gutierrez, V, Guerci-Bresler, A, Hjorth-Hansen, H, Karsenti, J, Kelly, K, Le Coutre, P, Martinez Chamorro, C, Oehler, V, Orti Pascual, G, Petzer, A, Pungolino, E, Rege-Cambrin, G, Rigal-Huguet, F, Roboz, G, Rousselot, P, Sanchez-Guijo, F, Sanz Santillana, G, Schafhausen, P, Scheid, C, Schmidt, S, Specchia, G, Steegmann, J, Stenke, L, Hochhaus A., Gambacorti Passerini C., Abboud C., Gjertsen B. T., Brummendorf T. H., Smith B. D., Ernst T., Giraldo-Castellano P., Olsson-Stromberg U., Saussele S., Bardy-Bouxin N., Viqueira A., Leip E., Russell-Smith T. A., Leone J., Rosti G., Watts J., Giles F. J., Abruzzese E., Akard L. P., Bosi A., Cervantes F., Charbonnier A., Di Raimondo F., Etienne G., Garcia Gutierrez V., Guerci-Bresler A. P., Hjorth-Hansen H., Karsenti J. M., Kelly K. R., Le Coutre P., Martinez Chamorro C., Oehler V. G., Orti Pascual G., Petzer A., Pungolino E., Rege-Cambrin G., Rigal-Huguet F., Roboz G. J., Rousselot P., Sanchez-Guijo F. M., Sanz Santillana G., Schafhausen P., Scheid C., Schmidt S., Specchia G., Steegmann J. L., Stenke L., Hochhaus, A, Gambacorti Passerini, C, Abboud, C, Gjertsen, B, Brummendorf, T, Smith, B, Ernst, T, Giraldo-Castellano, P, Olsson-Stromberg, U, Saussele, S, Bardy-Bouxin, N, Viqueira, A, Leip, E, Russell-Smith, T, Leone, J, Rosti, G, Watts, J, Giles, F, Abruzzese, E, Akard, L, Bosi, A, Cervantes, F, Charbonnier, A, Di Raimondo, F, Etienne, G, Garcia Gutierrez, V, Guerci-Bresler, A, Hjorth-Hansen, H, Karsenti, J, Kelly, K, Le Coutre, P, Martinez Chamorro, C, Oehler, V, Orti Pascual, G, Petzer, A, Pungolino, E, Rege-Cambrin, G, Rigal-Huguet, F, Roboz, G, Rousselot, P, Sanchez-Guijo, F, Sanz Santillana, G, Schafhausen, P, Scheid, C, Schmidt, S, Specchia, G, Steegmann, J, Stenke, L, Hochhaus A., Gambacorti Passerini C., Abboud C., Gjertsen B. T., Brummendorf T. H., Smith B. D., Ernst T., Giraldo-Castellano P., Olsson-Stromberg U., Saussele S., Bardy-Bouxin N., Viqueira A., Leip E., Russell-Smith T. A., Leone J., Rosti G., Watts J., Giles F. J., Abruzzese E., Akard L. P., Bosi A., Cervantes F., Charbonnier A., Di Raimondo F., Etienne G., Garcia Gutierrez V., Guerci-Bresler A. P., Hjorth-Hansen H., Karsenti J. M., Kelly K. R., Le Coutre P., Martinez Chamorro C., Oehler V. G., Orti Pascual G., Petzer A., Pungolino E., Rege-Cambrin G., Rigal-Huguet F., Roboz G. J., Rousselot P., Sanchez-Guijo F. M., Sanz Santillana G., Schafhausen P., Scheid C., Schmidt S., Specchia G., Steegmann J. L., and Stenke L.

Abstract

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.

Published
2020

46. Effect of Uncertainty During the Lunge in Fencing

Author

Gutiérrez-Dávila, M., Zingsem, C., Gutiérrez-Cruz, C., Girela Giles, F. J., and FJ Rojas

Subjects
lcsh:Sports, lcsh:GV557-1198.995, Motor control, fencing, neuropsychology, lcsh:Sports medicine, uncertainty, lcsh:RC1200-1245, biomechanics, reaction response, Research Article
Abstract

The aim of this study is to determine the effect that uncertainty, in relation to the probability of error, exerts on the reaction response and speed during the lunge in fencing. The participants were 18 regional-level fencers with over five years' experience. Force platforms under the feet recorded the horizontal components of the reaction forces, from which the kinematic parameters of the center of mass were calculated. An electronic system to present stimuli, controlled by a programmable clock, projected a target onto a screen that represented a plastron. In situations without uncertainty, the fencers had to lunge as swiftly as possible when a circle (the target) appeared in the center of the plastron, trying to touch the center of the circle with the tip of the sword. In situations with uncertainty, the fencers had the same target as in the previous situation but they received the information that they had to change the lunge into a defensive move if the target disappeared from the plastron during the action. The results indicate that the reaction time and the movement time increased with uncertainty. Although there were no differences for the horizontal velocity of the center of mass at the end of the acceleration phase, the mean horizontal velocity of the lunge was reduced by the effect of the uncertainty. Prior knowledge of the opponent´s possible action implies a reduction in uncertainty, reducing movement time as well as meaning faster execution, thereby increasing the success of the lunge in fencing. Key PointsReaction time (RT) and the movement time (MT) increase when doubts arise about being able to reach the target as planned during the lunge.The horizontal velocity of the lunge decreases by the effect of uncertainty due to the possibility that the events might not occur as planned.These results highlight the importance that tactical intent has in fencing for successfully predicting the defensive movements of the opponent during the attack.

Published
2014

49. Efecto de sobrecargas ligeras sobre el rendimiento del salto vertical con contramovimiento

Author

Gutiérrez Dávila, Marcos, González, C., Giles, F. J., Gallardo, D., and Rojas Ruiz, Francisco Javier

Subjects
Salto vertical, Sobrepeso, Vertical jump, Fuerza, Impulse, Biomechanics, Overweight, Impulso, Biomecánica, Force
Abstract

El propósito de este estudio ha sido determinar el efecto de diferentes sobrecargas ligeras sobre el impulso vertical, la velocidad del centro de masas y el máximo pico de potencia, durante la realización de dos saltos verticales máximos consecutivos. Han participado 28 deportistas practicantes de modalidades deportivas donde el salto vertical constituye una habilidad básica. Se ha utilizado una plataforma de fuerza, operando a 500 Hz, sincronizada temporalmente a una cámara de vídeo, que registraba a 210 Hz el plano sagital de los saltos realizados sobre la plataforma. Los resultados indican que, cuando se utilizan sobrecargas del 7,5% del peso corporal, el tiempo utilizado durante la fase de contramovimiento se incrementa. El impulso vertical y el pico de potencia no varían con el uso de los diferentes niveles de las sobrecargas utilizadas, sin embargo, la velocidad de despegue se reduce un porcentaje similar al incremento de la carga., The purpose of this study was to determine the effect of different light overloads on the vertical impulse, velocity of center of mass and peak power during two consecutive maximum vertical jumps. 28 athletes practicing different sports where vertical jump is a basic skill have participated. A force platform, operating at 500 Hz, temporally synchronized to a video camera, which recorded at 210 Hz the sagittal plane of the jumps were used for the analysis. The results have shown that when overloads of 7,5% of body weight were used , the time used for the counter- phase increased. The vertical impulse and peak power did not vary with the use of different levels of light overloads used in this study, however, the take-off velocity the CM was reduced with a similar percentage that increased the overload.

Published
2016

50. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Author

Hochhaus, A, primary, Masszi, T, additional, Giles, F J, additional, Radich, J P, additional, Ross, D M, additional, Gómez Casares, M T, additional, Hellmann, A, additional, Stentoft, J, additional, Conneally, E, additional, García-Gutiérrez, V, additional, Gattermann, N, additional, Wiktor-Jedrzejczak, W, additional, le Coutre, P D, additional, Martino, B, additional, Saussele, S, additional, Menssen, H D, additional, Deng, W, additional, Krunic, N, additional, Bedoucha, V, additional, and Saglio, G, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results